Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ono Pharmaceutical and twoXAR have signed a drug discovery research collaboration to jointly discover and develop novel, efficacious treatments to address unmet medical needs in a specific neurological disease.
Image: Ono Pharmaceutical and twoXAR have signed drug discovery research collaboration to jointly discover and develop novel treatments for specific neurological disease. Photo: courtesy of Thought Catalog / Unsplash.
Subscribe to our email newsletter
Under the agreement, twoXAR will use its proprietary artificial intelligence (AI ) technology to identify a set of lead compounds which demonstrate a novel mechanism of action and will be further optimized by Ono for potential drug candidates. twoXAR will also predict a set of hypotheses which suggest the efficacy and safety of such lead compounds for the therapy.
Ono and twoXAR will select several compounds with their hypotheses from this set to test in further validation study. Ono will retain exclusive rights to develop and commercialize the compounds obtained through thiscollaboration throughout the world, and in return, Ono will pay twoXAR research and license fees as well as development and sales milestones.
“We highly value twoXAR’s approach to help drug discovery because it enables rapid identification and in vitro and in vivo efficacy validation of new lead compounds,” said Toichi Takino, Corporate Officer Executive Director, Discovery & Research.
“By combining Ono’s drug discovery experience and twoXAR’s AI technology, we believe that we can increase the speed and probabilityof success in discovering and developing innovative first-in-class drugs to expand our neurological disease pipeline.”
“As we expand our portfolio of drug discovery programs through collaborations with experienced drug development teams, we are honored to enter this collaboration with Ono Pharmaceutical, having a rich history of drug development and our partnership represents their continual commitment to improve efficiency in R&D,” stated Andrew A. Radin, Co-Founder and CEO of twoXAR.
“twoXAR continues to grow its drug development partnerships internationally and this collaboration with Ono represents our second with a globally-operating, Japan-headquartered partner.”
twoXAR is an artificial intelligence-driven biopharmaceutical company that leverages its computational platform to identify promising drug candidates, de-risk the opportunities through preclinical studies, and progress drug product candidates into the clinic through industry partnerships.
Based in Mountain View, California, the twoXAR team includes experts in drug discovery and development, biomedical informatics, computational biology, data science and software development. Investors in twoXAR include SoftBank Ventures, the Andreessen Horowitz Bio Fund, OS Fund, CLI Ventures, and the Stanford-StartX Fund.
Source: Company Press Release
